Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed an informed consent form agreeing to take part in the study
• People whose liver cancer has been confirmed through a tissue sample (biopsy)
• People whose cancer has spread, cannot be surgically removed, or is considered locally advanced
• People who have not previously received any systemic (whole-body) anti-cancer treatment
• People aged 18 years or older
• People whose cancer can be measured using specific imaging guidelines (mRECIST criteria), including in some cases areas that were previously treated with radiation if the cancer has clearly grown back there
• People who have previously had chemoembolization, radioembolization, or radiotherapy and have largely recovered from any side effects of those treatments (confirm with trial site for specific recovery requirements)
• People with a reasonably good general level of physical functioning, as measured by a standard medical performance scale (confirm with trial site)
• People whose liver is still functioning at a certain level, known as Child-Pugh Class A (confirm with trial site)
• People whose liver cancer falls into a specific stage category (BCLC Stage C, or BCLC Stage B where local treatment is not considered appropriate) according to a standard liver cancer staging system

Who may not be able to join:

• People who have previously received certain types of immunotherapy treatments targeting PD-1, PD-L1, CTLA-4, or any other immune-based cancer therapy
• People who have been diagnosed with another cancer in the past 3 years, unless it was a skin cancer (basal cell type) or an early-stage cervical or breast cancer that was fully treated and removed
• People with a medical or psychiatric condition that the treating doctor considers would make participation in the trial unsuitable
• People who are currently taking part in another clinical trial or are within an exclusion period from a previous trial
• People who are under legal guardianship or a similar form of legal protection
• People with specific rare subtypes of liver cancer, including fibrolamellar HCC, sarcomatoid HCC, or a mixed liver and bile duct cancer
• People with uncontrolled fluid build-up around the lungs or heart, uncontrolled fluid in the abdomen, or a symptomatic abnormal body passage (fistula)
• People with cancer pain that is not well controlled and requires repeated hospitalisations or high-dose steroid treatment (treatable lesions should be treated with radiotherapy before joining)
• People with active cancer that has spread to the brain or the lining of the brain, unless previously treated and confirmed to be stable
• People with a history of brain confusion caused by liver disease (hepatic encephalopathy)
• People who have had a bleeding episode from untreated or incompletely treated swollen veins in the oesophagus or stomach in the past 6 months
• People with inadequate organ function, including serious heart conditions, unstable coronary artery disease, respiratory failure, uncontrolled infection, or another life-threatening condition

Important: Always verify eligibility with the trial site directly before applying.